At the end of Tuesday’s regular trading session, Galectin Therapeutics Inc. (NASDAQ: GALT) closed its shares at $1.80 up 34.85% or $0.73. The Galectin stock recorded a high volume of 18.09 million shares, compared to the average daily volume of 304.27K shares. GALT stock skyrocketed after launching a website designed for chronic diseases.
What is the website for?
The Galectin Therapeutics is dedicated to developing new therapies to help patients struggling with liver problems and cancer. GALT’s lead drug belapectin is a carbohydrate-based drug that interacts with the galectin-3 protein, which plays a role in multiple degenerative diseases, including inflammatory, fibrotic and malignant. Development revolves around the non-alcoholic steatohepatitis (NASH) with cirrhosis, the severe form of NASH-related fibrosis.
NAVIGATEnash.com, a dedicated trial website launched by Galectin Therapeutics, came online yesterday.
- GALT’s new website is intended for the purpose of educating patients and physicians on liver cirrhosis caused by NASH.
- NAVIGATE, the GALT’s innovative, seamless adaptive Phase 2b/3 study in NASH cirrhosis, will also be made available on the website.
- Unfortunately, NASH cirrhosis currently has no treatment to lessen its progress and prevent more serious complications.
- A patient and their families are invited to actively participate in the NAVIGATE Study, a clinical trial by GALT aimed at developing the first potential treatment for NASH-cirrhosis.
What GALT is eyeing on?
With the NAVIGATE Study, the goal of Galectin Therapeutics (GALT) is to prevent the development of esophageal varices, which have been linked to more serious complications of cirrhosis related to NASH.